These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 791234)

  • 21. Comparison of efficacy of ginger with various antimotion sickness drugs.
    Wood CD; Manno JE; Wood MJ; Manno BR; Mims ME
    Clin Res Pr Drug Regul Aff; 1988; 6(2):129-36. PubMed ID: 11538042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relative efficacy of the proposed Space Shuttle antimotion sickness medications.
    Hordinsky JR; Schwartz E; Beier J; Martin J; Aust G
    Acta Astronaut; 1982; 9(6-7):375-83. PubMed ID: 11541691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectivity of antimotion sickness drugs during artificial gravity simulations.
    Green JA
    Aerosp Med; 1973 Nov; 44(11):1255-60. PubMed ID: 4586812
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment of severe motion sickness with antimotion sickness drug injections.
    Graybiel A; Lackner JR
    Aviat Space Environ Med; 1987 Aug; 58(8):773-6. PubMed ID: 3632537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of sixteen anti-motion sickness drugs under controlled laboratory conditions.
    Wood CD; Graybiel A
    Aerosp Med; 1968 Dec; 39(12):1341-4. PubMed ID: 4881887
    [No Abstract]   [Full Text] [Related]  

  • 26. Scopolamine (hyoscine) for preventing and treating motion sickness.
    Spinks A; Wasiak J
    Cochrane Database Syst Rev; 2011 Jun; 2011(6):CD002851. PubMed ID: 21678338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transdermal scopolamine for motion sickness.
    Med Lett Drugs Ther; 1981 Oct; 23(21):89-90. PubMed ID: 7027000
    [No Abstract]   [Full Text] [Related]  

  • 28. Chlorpheniramine and ephedrine in combination for motion sickness.
    Buckey JC; Alvarenga DL; MacKenzie TA
    J Vestib Res; 2007; 17(5-6):301-11. PubMed ID: 18626140
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications.
    Nachum Z; Shupak A; Gordon CR
    Clin Pharmacokinet; 2006; 45(6):543-66. PubMed ID: 16719539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of antimotion sickness drugs on habituation to motion.
    Wood CD; Manno JE; Manno BR; Odenheimer RC; Bairnsfather LE
    Aviat Space Environ Med; 1986 Jun; 57(6):539-42. PubMed ID: 3718377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Three-years' experience of transdermal scopolamine: long-term effectiveness and side-effects.
    Shupak A; Gordon CR; Spitzer O; Mendelowitz N; Melamed Y
    Pharmatherapeutica; 1989; 5(6):365-70. PubMed ID: 2594820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coping with space motion sickness in Spacelab missions.
    Graybiel A
    Acta Astronaut; 1981; 8(9-10):1015-8. PubMed ID: 11543090
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of some effects of three antimotion sickness drugs on nystagmic responses to angular accelerations and to optokinetic stimuli.
    Collins WE; Schroeder DJ; Elam GW
    Aviat Space Environ Med; 1982 Dec; 53(12):1182-9. PubMed ID: 7159338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prevention of motion sickness in orbital flight.
    Graybiel A
    Life Sci Space Res; 1976; 14():109-18. PubMed ID: 11977268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Airsickness prevention in helicopter passengers.
    Estrada A; LeDuc PA; Curry IP; Phelps SE; Fuller DR
    Aviat Space Environ Med; 2007 Apr; 78(4):408-13. PubMed ID: 17484344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transderm scopolamine efficacy related to time of application prior to the onset of motion.
    Levy GD; Rapaport MH
    Aviat Space Environ Med; 1985 Jun; 56(6):591-3. PubMed ID: 4015572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Scopolamine (hyoscine) for preventing and treating motion sickness.
    Spinks AB; Wasiak J; Villanueva EV; Bernath V
    Cochrane Database Syst Rev; 2007 Jul; (3):CD002851. PubMed ID: 17636710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Scopolamine for preventing and treating motion sickness.
    Spinks AB; Wasiak J; Villanueva EV; Bernath V
    Cochrane Database Syst Rev; 2004; (3):CD002851. PubMed ID: 15266468
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of transdermal scopolamine against seasickness: a 3-day study at sea.
    Attias J; Gordon C; Ribak J; Binah O; Rolnick A
    Aviat Space Environ Med; 1987 Jan; 58(1):60-2. PubMed ID: 3814034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autogenic-feedback training exercise is superior to promethazine for control of motion sickness symptoms.
    Cowings PS; Toscano WB
    J Clin Pharmacol; 2000 Oct; 40(10):1154-65. PubMed ID: 11028255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.